A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Acronyms SWOG S1801
- 05 Dec 2023 Planned End Date changed from 30 Apr 2024 to 21 Sep 2024.
- 24 Oct 2023 Results (n=281) assessing Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801 presented at the 48th European Society for Medical Oncology Congress
- 02 May 2023 Planned End Date changed from 1 Sep 2023 to 30 Apr 2024.